(2S)-Methyl 2-(7-(4-allyl-7-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate → methyl (2S)-2-(4,32-dimethyl-29-oxa-5,7,8,26-tetrazaheptacyclo[24.6.2.16,9.110,14.02,7.015,20.030,34]hexatriaconta-1(33),2,4,6(36),8,10,12,14(35),15,17,19,23,30(34),31-tetradecaen-3-yl)-2-[(2-methylpropan-2-yl)oxy]acetate

Participants

Reaction Steps

A solution of (2S)-methyl 2-(7-(4-allyl-7-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(2′-(but-3-en-1-yl)-[1,1′-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.030 g, 0.045 mmol) in dry DCE (5 mL) was heated (70° C. oil bath) and then treated with Hoveyda-Grubbs Cat. 2nd Gen. (3 mg, 5 μmol). The reaction was stirred for 90 min. The solvent was removed and the intermediate was used immediately in the following step. LCMS (M+H)=643.4.

Provenance & Evidence